Phase 2 N=8 Treatment

Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease

Parkinson Disease

Bottom Line

View on ClinicalTrials.gov: NCT02212678 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2019

Primary outcome: Primary: Glutathione (GSH) Brain Levels — 0.93; 0.99 mM

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: N-acetylcysteine capsule (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Minnesota
Primary completion: Sep 2015

Outcome Measures

Outcome	Result	p-value
PRIMARY Glutathione (GSH) Brain Levels	0.93; 0.99	—

Summary

The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.

Eligibility Criteria

Inclusion Criteria

All participants must be 18 years or older
All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent
Individuals with medically stable Parkinson's disease (in the opinion of the investigator)
All participants must not have taken antioxidants NAC, glutathione, coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study
Absence of dementia in all subjects

Exclusion Criteria

Inability to undergo MRI scanning without sedation and other MRI counterindications, such as metal in the body (see section 7.3)
Medically unstable conditions as determined by the investigators
Pregnant or lactating or those women of child-bearing age that are not using acceptable forms of contraception
Diagnosis of asthma that is presently being treated with any medication, or past history of asthma/bronchospasm resulting in an emergency room visit, hospitalization or treatment
Unable to adhere to study protocol for whatever reason

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02212678). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.